Search Prime Contracts

W911QY21C0065

Definitive Contract

Overview

Government Description
SBIR PHASE I
Awardee
Place of Performance
Austin, TX 78732 United States
Pricing
Fixed Price
Set Aside
Small Business Set Aside - Total (SBA)
Extent Competed
Full And Open Competition After Exclusion Of Sources
Related Opportunity
None
Analysis Notes
Amendment Since initial award the Potential End Date has been extended from 11/02/21 to 11/12/21.
RX Bandz was awarded Definitive Contract W911QY21C0065 (W911QY-21-C-0065) for Sbir Phase I worth up to $167,469 by Joint PEO for Chemical, Biological, Radiological and Nuclear Defense in May 2021. The contract has a duration of 6 months and was awarded through SBIR Topic Design, Testing and Production of Shatter Resistant Autoinjector Formula Containers with a Small Business Total set aside with NAICS 541715 and PSC AC12 via direct negotiation acquisition procedures with 2 bids received.

SBIR Details

Research Type
Small Business Innovation Research Program (SBIR) Phase I
Title
Innovative Approach to Produce Shatter Resistant Auto-Injector Formula Containers
Abstract
Impact cracks and checks in Type I glass cartridges arising from damage during manufacturing, handling, and transportation can be prevented by incorporating a shrinkable, high-clarity elastomeric sheath around the exterior of the cartridge. Rx Bandz proposes to explore the addition of an energy-absorbing polymer jacket to the exterior of the cartridge surface, augmenting its strength and destroying defective units in production. Rx Bandz will design, develop, and test Type I 1mL cartridges reinforced with a perfluoroalkoxy (PFA), fluorinated ethylene propylene (FEP), or silicon jacket. These materials were considered for their shrink recovery, energy absorption and ease to integrate into a medical device. Assembly of the sheath over the cartridge will take advantage of the shrink recovery of the proposed elastomers by first expanding the sheath and then allowing it to recover around the cartridge. The compression of the recovered elastomer on the foot and shoulder of the cartridge permanently secures the sleeve. During assembly of the sheath, the elimination of critical defects resulting from upstream manufacturing processes is also considered. Destroying unidentified defective cartridges by exposing them to forces defined by the shrinking sheath will prevent failure during operation. This approach not only increases ruggedness and reliability, but also benefits from the low-cost and low-risk provided by maintaining a standard Type I pharmaceutical glass as the primary container. Rx Bandz' solution does not change properties of the glass or expose the pharmaceutical to new materials, which allows for leveraging existing data to demonstrate compliance with ISO 11608-1, ISO 13926, ISO 70788, and USP 661 (protection, delamination, chemical composition, compatibility, clarity, quality, etc). This low-risk design's success in increasing ruggedness by using energy absorption to protect brittle materials against impact and vibration is well documented. Energy absorption protects the glass from cracks and scratches that would increase criticality and weaken strength. Strength property of glass is not constant, but rather defined by its surface quality arising from the defect disturbances. Eliminating and preventing these defects are essential to mitigate the risk of a cartridge fracturing during use. A protection system of this type increases the ruggedness and reliability of the cartridge during the lifetime of the auto-injector.
Research Objective
The goal of phase I is to establish the technical merit, feasibility, and commercial potential of proposed R&D efforts and determine the quality of performance of the small business awardee organization.
Topic Code
CBD202-003
Agency Tracking Number
C202-003-0006
Solicitation Number
20.2
Contact
Myrna Walsh

Status
(Complete)

Last Modified 3/14/23
Period of Performance
5/12/21
Start Date
11/12/21
Current End Date
11/12/21
Potential End Date
100% Complete

Obligations
$167.5K
Total Obligated
$167.5K
Current Award
$167.5K
Potential Award
100% Funded

Award Hierarchy

Definitive Contract

W911QY21C0065

Subcontracts

0

Activity Timeline

Interactive chart of timeline of amendments to W911QY21C0065

Transaction History

Modifications to W911QY21C0065

People

Suggested agency contacts for W911QY21C0065

Competition

Number of Bidders
2
Solicitation Procedures
Negotiated Proposal/Quote
Evaluated Preference
None
Commercial Item Acquisition
Commercial Item Procedures Not Used
Simplified Procedures for Commercial Items
No

Other Categorizations

Subcontracting Plan
Plan Not Required
Cost Accounting Standards
Exempt
Business Size Determination
Small Business
Defense Program
None
DoD Claimant Code
Services
IT Commercial Item Category
Not Applicable
Awardee UEI
DXRED7S6FVE9
Awardee CAGE
7N2K8
Agency Detail
Awarding Office
W911QY W6QK ACC-APG NATICK
Funding Office
W56XNH
Created By
dan.l.adams2.civ@army.mil
Last Modified By
dan.l.adams2.civ@army.mil
Approved By
dan.l.adams2.civ@army.mil

Legislative

Legislative Mandates
None Applicable
Performance District
TX-37
Senators
John Cornyn
Ted Cruz
Representative
Lloyd Doggett
Modified: 3/14/23